UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000059848
Receipt number R000068437
Scientific Title Maintenance of antidepressant effect by magnetic modulation (rTMS) among patients with treatment-resistant depression who responded to low dose ketamine infusion: a double-blind randomized sham rTMS-controlled study
Date of disclosure of the study information 2026/06/01
Last modified on 2026/06/01 17:29:37

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Maintenance of antidepressant effect by magnetic modulation (rTMS) among patients with treatment-resistant depression who responded to low dose ketamine infusion: a double-blind randomized sham rTMS-controlled study

Acronym

Ketamine+rTMS Study

Scientific Title

Maintenance of antidepressant effect by magnetic modulation (rTMS) among patients with treatment-resistant depression who responded to low dose ketamine infusion: a double-blind randomized sham rTMS-controlled study

Scientific Title:Acronym

ketamine+rTMS study

Region

Asia(except Japan)


Condition

Condition

Treatment-resistant depression (TRD)

Classification by specialty

Psychiatry

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

If the efficacy of ketamine infusion + rTMS is greater than ketamine + srTMS, it will approve prolongation/enhancement of ketamine efficacy by physical electronic stimulation and will provide a novel treatment strategy for patients with TRD in the future.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

MRI,MADRS,HAMD

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Cluster

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Ketamine 0.5mg+rTMS

Interventions/Control_2

Ketamine 0.5mg+sham rTMS

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

70 years-old >=

Gender

Male and Female

Key inclusion criteria

Major depressive episode including unipolar and bipolar depression, according to
DSM-5 criteria and MINI (Mini International Neuropsychiatric Interview;MINI)
diagnostic interview

Key exclusion criteria

1)Major medical conditions e.g.:head injury, epilepsy, severe renal diseases and cancer.
2)Other axis I psychiatric disorders such as schizophrenia, delusional disorder, organic brain syndrome, and dementia.
3)Pregnancy and Breastfeeding women
4)Substance abuse in previous 6 months such as cocaine, marijuana, opium, ketamine, PCP phencyclidine.
5)Current use of NMDA receptor antagonist Amantadine, Rimantadine, Lamotrigine,Memantine, Dextromethorphan
6)Alcohol abuse and dependence within 6 months.
7)Allergy to Ketamine and Rapamycin.
8)Implanted cardiac pacemaker within 30 cm or metal material like vessel clip in the brain.
9)Those are unable to express willingness to participate.

Target sample size

80


Research contact person

Name of lead principal investigator

1st name Tung-Ping
Middle name Tom
Last name Su

Organization

Cheng-Hsin General Hospital

Division name

Department of Psychiatry

Zip code

112

Address

No.45,Cheng Hsin St.,Pai-Tou,Taipei, Taiwan (R.O.C.)

TEL

+886-928593009

Email

tomsu0402@gmail.com


Public contact

Name of contact person

1st name Tung-Ping
Middle name Tom
Last name Su

Organization

Cheng-Hsin General Hospital

Division name

Department of Psychiatry

Zip code

112

Address

No.45,Cheng Hsin St.,Pai-Tou,Taipei, Taiwan (R.O.C.)

TEL

+886-928593009

Homepage URL


Email

tomsu0402@gmail.com


Sponsor or person

Institute

Su Kunbo Medical Research Foundation

Institute

Department

Personal name



Funding Source

Organization

Su Kunbo Medical Research Foundation

Organization

Division

Category of Funding Organization

Outside Japan

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Cheng-Hsin General Hospital

Address

No.45,Cheng Hsin St.,Pai-Tou,Taipei, Taiwan (R.O.C.)

Tel

886-2-28264400

Email

irb@chgh.org.tw


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

Cheng-Hsin General Hospital


Other administrative information

Date of disclosure of the study information

2026 Year 06 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2024 Year 03 Month 01 Day

Date of IRB

2024 Year 03 Month 01 Day

Anticipated trial start date

2024 Year 03 Month 01 Day

Last follow-up date

2025 Year 11 Month 21 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2025 Year 11 Month 21 Day

Last modified on

2026 Year 06 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068437